Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The study group was 96 children.

By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.

In this double-blind, randomized clinical trials, 96 children (2-18 years) were enrolled to placebo and vitamin D groups.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some children received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

ADHD symptoms were diagnosed by Conners parent rating scale (CPRS) test at baseline and after intervention.

ADHD Conners divided into inattention (IA), hyperactivity/impulsivity (H/I) and combination type (C) subscales.

What Was Measured

Topics PubMed links to this paper include Attention Deficit Disorder with Hyperactivity, Vitamin D and Vitamins.

Author keywords: Attention-deficit hyperactivity disorder, Children and Conners parent rating scale.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 96 children.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (World journal of pediatrics : WJP), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.